Haleon Stock - weekly review after Redburn downgrade and soft 2026 performance
22.06.2026 - 00:02:10 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/21/2026, 22:05 UTC. Details in the imprint.
Haleon (GB00BMX86B70) spent the past week under modest pressure as investors digested a broker downgrade and soft share performance in 2026. According to a recent Bez Kabli market round-up, the consumer-health group has fallen behind the FTSE 100 so far this year.
All news and analysis on Haleon stock
Key articles, background pieces and price data help put Haleon’s latest broker moves and trading performance into perspective for retail investors.
What Bez Kabli reports on the week
In a sector recap dated 06/19/2026, Bez Kabli noted that Haleon shares closed Friday at 334 pence, edging up 0.06% on the day. That small move capped a week in which the stock nevertheless continued to lag the broader UK market.
The same report highlighted that Haleon shares are down nearly 11% in 2026, compared with a roughly 1% decline for the FTSE 100 over the same period. The underperformance underscores how the stock’s defensive profile has not translated into stronger returns this year.
Redburn downgrade and peer context
Bez Kabli also pointed out that Redburn downgraded Haleon to Neutral with a 365 pence price target, adding pressure to sentiment around the stock. The broker move reflects tempered expectations for a rapid recovery in growth, particularly in the key U.S. market.
Within the broader European consumer-health and pharmaceuticals universe, Haleon’s year-to-date share decline contrasts with more resilient or even positive moves at some peers, according to the same weekly summary. Against this backdrop, the downgrade has helped crystallize concerns about Haleon’s relative momentum.
Background on growth and risk profile
Beyond the near-term rating action, Haleon’s fundamental profile remains relatively defensive. External analytics providers describe the group’s risk characteristics as low-beta, reflecting smaller swings than the market during broader sell-offs. This has historically appealed to investors seeking stability in healthcare exposure.
At the same time, independent financial-health analysis points to a solid balance sheet and good operating efficiency, with Haleon scoring strongly on profitability metrics versus pharmaceutical peers. That financial resilience gives management room to navigate softer patches in regional demand.
The business behind the stock
Haleon generates most of its revenue from over-the-counter consumer health brands across oral health, pain relief, respiratory, digestive health and vitamins. Well-known names in its portfolio include Sensodyne toothpaste, Voltaren pain relief gel and the Advil painkiller range.
Where the stock trades today
The shares of Haleon (GB00BMX86B70) trade on the London Stock Exchange in GBP; a reliably verified current price and market capitalization were not available at 06/21/2026, 22:05 UTC.
Key facts on Haleon stock
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Ticker: HLN
- Venue: London Stock Exchange
- Sector / Industry: Consumer Health / Healthcare
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
